The European Society for Medical Oncology Gynaecological Cancers Annual Congress 2025 (ESMO Gyn 2025)

A prospective analysis demonstrates the effectiveness of HPV vaccination in reducing progression to biopsy-confirmed precancerous lesions and HPV persistence in a cohort of South Korean women in off-label age groups.

The cadherin 6 (CDH6)-directed antibody–drug conjugate raludotatug deruxtecan elicits response in heavily pretreated patients with platinum-sensitive ovarian cancer while having a manageable safety profile, according to a subgroup analysis of an ongoing first-in-human phase I trial.

Maintenance with the PARP inhibitor rucaparib after first-line platinum-doublet chemotherapy and cytoreductive surgery appears to reduce the risk of progression in the homologous recombination deficiency (HRD)-negative population of patients with advanced, high-grade ovarian cancer enrolled in the phase III ATHENA-MONO trial, no matter the prognostic factor.

Selinexor maintenance therapy continues to show consistent clinical benefit in patients with TP53 wild-type (TP53wt) advanced or recurrent endometrial cancer, regardless of mismatch repair (MMR) status, according to the ENGOT-EN5/GOG-3055/SIENDO trial presented at ESMO Gyn 2025.